Full title: (Peak) A Phase 3 Randomised Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumours
Age: 18+
Phase: 3
Locations:
- Cambridge – Addenbrooke’s Hospital
- Glasgow – Beatson West of Scotland Cancer Centre
- London – University College London Hospital (UCLH), Guy’s Hospital
- Manchester – The Christie NHS Foundation Trust
- Sheffield – Sheffield Teaching Hospital NHS Foundation Trust
- Sutton – Royal Marsden Hospital
Brief summary:
The treatment is a drug known as CGT9486 in combination with sunitinib, which will be compared with just treatment using sunitinib. This is a multi-part study that will look at the dose of CGT9486 to be used in a subset of patients who have previously been treated for GIST, look at interactions between the new treatment drug and previous treatments of tyrosine kinase inhibitors (TKIs) for GISTS, and investigate the efficacy of the new treatment in patients whose imatinib treatment was not effective.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
